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Galactosamine induces a dose-dependent hepatic in-
jury in rats and many other animals. The toxicity of D-
galactosamine appears to be a consequence of the loss of 
hepatic UTP. It has previously been reported that re-
generating liver cytosol is able to prevent, at least in 
part, the lethal effect of this substance by stimulating 
hepatic regeneration. Recently, we have separated a 
fraction using alcohol precipitation (80%) from regen-
erating liver cytosol and from weanling rat liver cytosol 
prepared in acetate buffer (100 mM, pH 6.5). We named 
this fraction hepatic stimulatory substance because of 
its ability to stimulate DNA synthesis in vivo when 
injected intraperitoneally in 40% hepatectomized rats 
and in vitro in the presence of hepatocytes isolated and 
maintained in monolayer cultures. The stimulatory ac-
tivity of the hepatic stimulatory substance is fully evi-
dent in subfractions of molecular weight up to 300,000 
and 50,000 daltons of the crude material obtained using 
Amicon Ultra membrane filters. The present report de-
scribes the ability of hepatic stimulatory substance and 
its subfractions to stimulate hepatocyte proliferation 
and the application of these hepatic extracts in success-
fully reversing the lethality of o-galactosamine-induced 
hepatic necrosis in rats. o-Galactosamine (2.6 gm per 
kg of body weight) was administered intraperitoneally 
to 438 male Lewis strain rats. The·animals were divided 
into six groups according to the type of treatment: Group 
1 (n = 131) saline; Group 2 (n = 40) cytosol (75 mg total 
protein); Group 3 (n = 75) hepatic stimulatory substance 
(20 mg total protein); Group 4 (n = 42) 300,000 subfrac-
tion (4 mg total protein); Group 5 (n = 68) 300,000 
subfraction (2 mg total protein), and Group 6 (n = 82) 
50,000 subfraction (0.6 mg total protein). All rats re-
ceived 4 ml of the test solution intraperitoneally at 48 
hr after o-galactosamine administration. The percent-
age of rats surviving in each group was determined daily 
for 20 days. Although hepatic stimulatory substance and 
50,000 subfraction tended to improve survival in intox-
icated rats, only those rats treated with the 300,000 
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sub fraction attained statistical significance with respect 
to the saline control. 
A major objective of clinical hepatology is the devel-
opment of a successful method for the treatment of 
fulminant acute hepatic failure, a disease which presently 
has an extremely poor prognosis and carries a high 
mortality (1). Various treatment modalities, including 
plasmapheresis, exchange transfusion, cross-circulation, 
heterotopic liver transplantation and charcoal hemoper-
fusion have been developed and used for this condition 
in humans. More recent attempts to study this entity 
and evaluate new methods of treatment have utilized 
reproducible, potentially reversible, animal models of 
fulminant hepatic failure which duplicate, at least in 
part, the pathophysiological conditions found in human 
fulminant hepatic failure. One of these models (2-4), 
that of D-galactosamine (D-GAL) intoxication, has re-
ceived wide attention because of its reproducible dose/ 
response relationship, its reversibility and its histologic 
similarity to that described in human fulminant hepatic 
failure. Numerous reports in the past years have indi-
cated that, in rats with experimental acute hepatic fail-
ure, the administration of various liver fractions is able 
to significantly improve animal survival by stimulating 
hepatic regeneration (5-11). 
We have recently described a protein fraction which is 
derived by alcohol precipitation of regenerating liver 
cytosol (RLC), which is able to stimulate DNA synthesis 
and cell proliferation both in vivo, when injected intra-
peritoneally into 40% hepatectomized rats, and in vitro 
when added to hepatocytes maintained in monolayer 
cultures (Francavilla, A. et aI., Hepatology 1982; 2:701, 
Abstract). The stimulatory activity of this hepatic stim-
ulatory substance (HSS) is fully evident in subfractions 
of molecular weight uup to 300,000 and 50,000 daltons 
of the crude material obtained using Amicon ultra mem-
brane filters. The present report further describes the 
ability of HSS and its subfractions to stimulate hepato-
cyte proliferation and the application of these hepatic 
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extracts in successfully reversing the lethality of D-GAL-
induced hepatic necrosis in rats. 
MATERIALS AND METHODS 
Animals. Male Lewis strain rats (200 to 230 gm) pur-
chased from Hilltop Lab Animals (Scottdale, Pa.) were kept in 
a temperature- and light-controlled room (6 a.m. to 6 p.m.), 
and received food and water ad libitum. Forty per cent and 70% 
partial hepatectomy (PH) were performed between 7:30 and 
9:00 a.m. using the method of Higgins and Anderson (13). All 
rats were fasted for 12 hr prior to the injection of D-GAL and 
prior to the performance of PH. Food and water were then 
offered ad libitum 3 hr after the performance of the above. 
Materials. Collagenase Type I (125 to 250 units per mg) 
was obtained from Worthington Diagnostic Systems (Freehold, 
NJ). Minimum essential medium and fetal calf serum were 
purchased from GIBCO Laboratories (Grand Island, NY). In-
sulin, epidermal growth factor (EGF), 3,3" -5-triiodothyronine, 
glucagon, HEPES and pyruvic acid were purchased from Sigma 
Chemical Company (St. Louis, Mo.) Methyl-[3H]thymidine (50 
to 80 Ci per mmole) was obtained from New England Nuclear 
(Boston, Mass.). D-GAL hydrochloride (Sigma Chemical Co.) 
was reconstituted in 5% dextrose immediately prior to use, and 
the pH was adjusted to 6.88. 
Preparation of Hepatic Extracts 
RLC. Twenty-four hours after 70% PH in normal adult 
Lewis rats, the regenerating liver remnants were excised and 
placed in 4 volumes (w/v) of ice-cold buffer [0.27 M sucrose, 
12 mM Tris-HCI, 1 mM EDTA (pH 7.6)], and a crude homog-
enate was prepared using a Potter-Elveljein tissue grinder. This 
crude homogenate was centrifuged for 10 min at 10,000 X g at 
4°C, and the resultant supernatant was further ultracentrifuged 
for 1 hr at 100,000 X g. The resultant pellet contained mem-
brane components, and the supernatant contained the cytosolic 
components (RLC). 
HSS and Its Subfractions (300,000 and 50,000). 
HSS was prepared essentially by the method previously re-
ported by LaBrecque (14, 15). A 35% (w/v) homogenate in ice-
cold acetate buffer (100 mM, pH 4.65) was prepared from pooled 
regenerating livers and was heated at 65°C for 15 min with 
further centrifugation at 30,000 X g for 20 min at 4°C. The 
resulting supernatant was added to 6 volumes of cold ethanol. 
This mixture was stirred for 2 hr at 4°C and centrifuged at 
37,000 X g for 20 min at 4°C. The resulting pellet, which 
represented HSS, was dissolved in H20 and stored frozen at 
-70°C when not used immediately. The subfractions (300,000 
and 50,000) were prepared separately by filtering HSS through 
Amicon ultramembrane filters with molecular weight limit 
exclusion of 300,000 (XM 300,000) and 50,000 (XM 50,000) 
using the filtrate for the injection in the rats. Although identical 
fractions have been prepared from normal intact livers, these 
were not used in the present studies, since we have already 
demonstrated their lack of hepatic stimulatory activity in vitro 
and in vivo (Francavilla A, et aI., Hepatology 1982; 2:701, 
Abstract). 
Determination of Proliferative Activity of HSS and 
300,000 Subfraction 
In Vivo Experiments. In vivo experiments were per-
formed using methods previously described by LaBrecque and 
Pesch (14). A heightened background of in vivo DNA synthetic 
activity was induced in host rats by 40% PH. Six hours later, 
these rats received 4 ml of saline, HSS (20 mg of protein) and 
300,000 (2 mg of protein) subfraction solution intraperitoneally. 
Eighteen hours later 50 !lCi of [3H]thymidine (specific activity 
= 76.6 Ci per mmole) was administered intraperitoneally. Rats 
were killed 2 hr later, and liver samples were taken for the 
determination of DNA content (16). eH]thymidine incorpora-
tion (12), the percentage oflabeled nuclei and the mitotic index, 
as previously described (12). The augmentation of these param-
eters in the liver beyond the modest response that usually 
follows 40% hepatectomy was considered to be a demonstration 
of the proliferative activity of liver extracts. Augmentation of 
proliferation resulting from liver extract administration was 
considered present when all three parameters were significantly 
elevated when compared to the response observed following 
40% PH alone. 
In Vitro Experiments. These experiments evaluated the 
effect ofliver extracts on DNA synthetic activity in hepatocytes 
maintained in primary cultures. Hepatocytes were prepared by 
a modification of the two-step collagenase perfusion technique 
of Seglen (17) as reported by Jirtle et al. (18) The liver was 
perfused retrograde via cannula in the inferior vena cava with 
250 ml buffer [142 mM NaCI, 6.7 mM KCI, 10 mM HEPES 
(pH 7.4)] followed by 250 ml of the same buffer containing in 
addition 5.7 mM CaCl2 and 0.5 mg per ml collagenase. Hepa-
tocytes were dispersed and washed twice with cold Ca++-free 
perfusion buffer and resuspended in minimal essential medium 
supplemented with pyruvate (1 mM), aspartate (0.2 mM), 
serine (0.2 mM), gentamycin (40 !lg per ml) and in addition 
insulin (10-7 M) and 5% fetal calf serum. oepato~yte viabilit; 
was determined by trypan blue exclusion. Only preparations 
having greater than 90% viability were used. Cell number was 
determined using a hemocytometer. 
Hepatocytes were plated at a cell density of 2 x 105 per 35 
mm Falcon "Primaria" tissue culture dish in 1.5 ml medium 
and maintained at 37°C in a 5% CO2 atmosphere. Following a 
3-hr. period to allow for attachment of the hepatocytes, the 
medIUm was changed and the cells were left for 72 hr. ['lH] 
Thymidine (7.5 !lCi per dish) was added for the last 24 hr. Each 
experimental group comprised four dishes so that when the 
cells were harvested, one dish was used to determine DNA 
concentration using a microfluorometric method (19). Two 
dishes were used to determine ['JHjthymidine incorporation 
using the method described by Michalopoulos et al. (20) and 
one dish was used to determine labeling index by autoradiog-
raphy (20). 
Model of D-GAL-Induced Acute Hepatic Failure and 
Preventing Action of Hepatic Extracts 
Development of Model. In preliminary experiments, 4 
ml of D-GAL were administered intraperitoneally to Lewis 
strain rats using a range of dosages (1.8 to 2.6 gm per kg of 
body weight). Survival in such animals was observed during a 
period of 20 days (Figure 1). A dose of 2.6 gm per kg of body 
weight of D-GAL resulted in consistent, reproducible mortality 
as a result of massive hepatic necrosis and was therefore used 
for all experiments reported here. 
Experimental Protocol. D-GAL (2.6 gm per kg of body 
weight) was administered intraperitoneally to 438 male Lewis 
strain rats. The animals were divided into six groups according 
to the type of treatment as reported in Table 1. The doses of 
all fractions used are related to the total protein concentration 
of the starting cytosol, so that, 75 mg of cytosol contain 20 mg 
of HSS, 2 mg of 300,000 subfraction solution and 0.6 mg of 
50,000 subfraction solution. 
All rats received 4 ml of the test solution intraperitoneally 
at 48 hr after D-GAL administration. This time of injection of 
an hepatic stimulatory factor had already been shown to be 
optimal in an identical model of hepatic failure (7). The percent 
of rats surviving in each group was determined daily for 20 
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FIG. 1. Per cent survival of Lewis strain rats receiving different 
concentrations of D-GAL. Sixty rats (20 per each group) were injected 
intraperitoneally with different dosages of D-GAL: 1.8 grn per kg of 
body weight = 0; 2 grn per kg of body weight = Ii; 2.6 grn per kg of 
body weight = O. 
TABLE 1. Groups of animals, number of rats and treatment 
used after 48 br injection of D-GAL (2.6 gm per kg of body 
weight) 
Groups No. of Intraperitoneal treatment Total protein 
animals injected (mg) 
1 131 4 ml of saline 
2 40 4 ml of cytosol 75 
3 75 4 ml ofHSS 20 
4 42 4 ml of 300,000 subfraction 4 
5 68 4 ml of 300,000 subfraction 2 
6 82 4 ml of 50,000 subfraction 0.6 
Protocol for studying the effect of liver fractions on survival after 
D-GAL-induced acute hepatic failure. The doses used were related to 
the starting cytosol; 75 mg of cytosol protein dose contain 20 mg of 
protein of HSS, 2 mg of protein of 300,000 subfraction and 0.6 mg of 
protein of 50,000 subfraction. 
days. The DNA synthetic activity and hepatic nuclear-labeling 
index were evaluated in a separate group of 30 rats intoxicated 
with D-GAL (2.6 gm per kg of body weight). Three groups of 
10 intoxicated rats treated with saline (control), HSS and 
300,000 subfraction received [3Hjthymidine intraperitoneally 
at 48 hr after extract administration and 96 hr after D-GAL 
administration. The rats were sacrificed 2 hr later, and liver 
samples were taken and processed for nuclear incorporation of 
[3Hjthymidine, labeling index and autoradiography as de-
scribed previously. 
Other Assays 
The protein concentration of each fraction was determined 
using Lowry et al.'s (21) method and using bovine serum 
albumin as standard. The radioactive content of samples was 
determined in a Packard Tri-carb liquid scintillation spectrom-
eter. Results are expressed as mean ± S.E. 
Statistical Analysis 
The odds ratio was used to assess relative risk or the odds in 
favor of survival associated with specific treatments. The con-
fidence intervals were constructed using logarithms (to the base 
e) (22). When the confidence interval excluded unity (odds 
ratio equal to one), indicating a significant degree of associa-
tion, the significance of the association was then tested using 
x2; the continuity correction was used when the n was less than 
50 or an expected value was less than 5. A p value of less than 
0.05 was considered statistically significant. 
RESULTS 
The ability of HSS and its subfractions to stimulate 
hepatic regeneration was evaluated both in vivo and in 
vitro. Table 2 demonstrates the effect ofHSS and 300,000 
subfraction on in vivo DNA synthesis and hepatocyte 
proliferation in 40% hepatectomized rats. Hepatic incor-
poration of tritiated thymidine (DNA synthesis) was 
significantly increased from 14,520 ± 856 in the control 
group to 46,750 ± 15,820 in the group treated with HSS, 
and to 31,150 ± 4,850 in the group treated with 300,000 
sub fraction. 
Similarly, following HSS and 300,000 subfraction 
treatment, the per cent of labeled nuclei increases from 
a value of 11.5 ± 3 to values of 35.8 ± 5 and 28.8 ± 5, 
and the percentage of mitoses increased from 0.6 ± 0.2 
to 2.6 ± 0.8 and 2.2 ± 0.3. 
The ability of HSS and its sub fractions to stimulate 
hepatocyte proliferation was confirmed also in vitro and 
is listed in Table 3. HSS, 300,000 subfraction and 50,000 
subfraction stimulated incorporation of [3H]thymidine 
into hepatocyte nuclei, and enhanced the labeling index 
of hepatocytes in primary cultures. It should be noted 
that the in vitro stimulatory activity was observed in the 
presence of insulin and EGF. We have previously dem-
onstrated no stimulatory activity when these two com-
ponents were removed from the culture medium (23). A 
comparison of the stimulatory activity of 300,000 and 
50,000 subfractions, in vivo and in vitro, showed that the 
filtrate retained 80% of the stimulatory activity as com-
pared with the membrane-retained activity. 
The effect of varying the dose of D-GAL administra-
tion on rat survival (dose-response relationship) is de-
picted in Figure 1. Three groups of 20 rats each received 
D-GAL at concentrations of 2.6, 2.0 and 1.8 gm per kg 
of body weight. Although there was no statistical differ-
ence in rat survival among the 3 doses, the reproducible 
mortality was greatest at the highest dose (2.6 gm per kg 
of body weight), and no mortality was observed during 
the first 40 to 48 hr. The dosage of 2.6 gm per kg of body 
weight was used for all subsequent experiments. Animal 
death was evaluated daily for 20 days, but no additional 
change in mortality was observed after the tenth day. 
Figure 2 demonstrates the effect of cytosol and HSS 
on the survival of rats receiving D-GAL at dosage of 2.6 
gm per kg of body weight. Forty-eight hours following 
D-GAL intoxication, 4 ml of cytosol (protein content = 
75 mg) were injected intraperitoneally into 40 animals, 
and 4 ml of HSS prepared as described above (protein 
content = 20 mg) were injected intraperitoneally into 75 
animals. The mortality rate was determined daily and 
compared with that of a control group of 131 animals 
which had been injected intraperitoneally with 4 ml of 
saline. Both RLC and HSS administration improved the 
survival rate ofthe animals when compared to the control 
group. However, only the effect of HSS was statistically 
significant, during the first 5 days. In fact, at the fifth 
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TABLE 2. Effect of HSS on hepatocyte proliferation activity in vivo 
Protein DNA synthesis % labeled Treatment concentration (cpm/mg of DNA) p< nuclei p< % mitoses p< (mg) 
Saline 14,520 ± 856 11.5 ± 3 0.6 ± 0.2 
HSS 20 46,750 ± 15,820 0.05 35.8 ± 5 0.05 2.6 ± 0.8 0.05 
300,000 sub fraction 2 31,150 ± 4,850 0.05 28.8 ± 5 0.05 2.2 ± 0.3 0.05 
Thirty rats with 40% hepatectomy were used. Six hours following hepatectomy, 10 rats received 4 ml of HSS (20 mg), 10 rats 4 ml of 300,000 
subfraction (2 mg) and 10 rats 4 ml of saline solution. Eighteen hours following the injection of the extract, 50 "Ci of pHjthymidine was injected 
intraperitoneally, and 2 hr later the rats were sacrificed. DNA synthesis, per cent labeled nuclei and per cent mitoses were determined as reported 
in "Materials and Methods." The values are expressed as mean ± SE. 
TABLE 3. Effect of HSS on hepatocyte proliferation in vitro 
Medium additions Protein DNA synthesis p< % labeled nuclei p< ("g/mI) (cpm/"g of DNA) 
-0- -0- 1,630 ± 210 1 ± 0.3 
15 ± 4.3 
26 ± 3.8 
28± 3.6 
Insulin + EGF -0- 19,231 ± 1,270 
Insulin + EGF + HSS 10 30,028 ± 1,280 0.02 
0.05 
0.02 
0.05 Insulin + EGF + 300,000 5 29,128 ± 983 
subfraction 
Insulin + EGF + 50,000 5 31,322 ± 1,480 0.05 29 ± 5.8 0.05 
subfraction 
Hepatocytes were incubated as described in "Materials and Methods." Cells were plated in minimal essential medium supplemented with fetal 
calf serum and insulin. After 3 hr, the medium and the floating cells were removed and serum-free minimal essential medium added, plus the 
hormones or extracts as indicated. Cultures were exposed to 5 "Ci of [3Hjthymidine/ml for 24 hr and processed after 72 hr for determination of 
DNA synthesis. The hormone concentrations were: insulin, 10-7 M and EGF, 10 ng/ml. Triplicate culture dishes were set up for each treatment. 
The results are expressed as the mean ± S.E. of 12 dishes for four different experiments. Labeling of nuclei was determined by autoradiography 
and expressed as per cent of total nuclei. The statistical analysis was made comparing the value of each extract with that observed in the 
presence of insulin and EGF. The values are expressed as mean ± S.E. 
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FIG. 2. Per cent survival of D-GAL-intoxicated (2.6 gm per kg of 
body weight) rats treated with cytosol 75 mg = e and HSS (20 mg) = 
., compared with control groups tested with saline = .... *, p < 0.02. 
day, the odds of survival in this group were 2.5-fold more 
than that of the control group (odds ratio = 2.44; 95% 
CI: 4.96, 1.20; x2 = 6.21; p < 0.02). 
Figure 3 depicts the survival curves for rats receiving 
the 300,000 and 50,000 subfractions of HSS. Forty-eight 
hours following D-GAL intoxication, 4 ml of 300,000 
subfraction (total protein content = 2 mg) were injected 
intraperitoneally in 68 animals, and 4 ml of 50,000 
subfraction (total p:t;otein content = 0.6 mg) were injected 
in 82 animals. The mortality rate was determined daily 
and compared with that of the control group of 131 
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FIG. 3. Per cent survival of D-GAL-intoxicated rats (2.6 gm per kg 
of body weight) treated with 300,000 subfraction (4 mg) = e, 300,000 
subfraction (2 mg) = 0 and 50,000 subfraction (0.65 mg) = D, compared 
with control groups treated with saline = .... *, p < 0.005; +, p < 0.001. 
animals injected with 4 ml saline. The 300,000 subfrac-
tion injection resulted in a significant improvement in 
survival; the odds in favor of survival were significantly 
increased at all time points beyond 4 days (p < 0.005 and 
p < 0.001). To confirm these results, 4 ml of 300,000 
subfraction with double concentration of protein (4 mg) 
were injected in 42 rats 48 hr after D-GAL intoxication. 
Also, in this case, at all points beyond 4 days, a significant 
improvement of survival was achieved compared to the 
control group (p < 0.005 and p <;.. 0.001). Although the 
-------------------------
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per cent of alive animals was higher in the latter group 
receiving 4 mg of 300,000 subfraction, a statistical differ-
ence with the group of animals receiving 2 mg of 300,000 
subfraction was not detected. No significant improve-
ment in survival was observed with the 50,000 subfrac-
tion. 
Table 4 demonstrates the DNA synthetic activity (cpm 
per mg DNA) and the labeling index found in rats 
intoxicated with D-GAL, and sacrificed 48 hr after the 
injection of HSS, 300,000 subfraction and saline. The 
results confirm that both of these fractions significantly 
increase DNA synthesis and labeling index. 
DISCUSSION 
The management of human fulminant hepatic failure 
remains very disappointing despite the evaluation of a 
multitude of treatment modalities. The goal of all these 
treatments is to support the patient temporarily in order 
to allow the injured host liver to regenerate. 
Since initial reports suggesting a role for insulin and 
glucagon in liver regeneration (24, 25), these two hor-
mones have been used as a potential treatment for acute 
hepatic failure both in animals and humans. Despite 
the encouraging initial data reported in animals (26), 
such treatments have shown no consistent effect in 
humans (27). 
Nonetheless, the concept of promoting hepatic regen-
eration in an injured liver presents an attractive alter-
native and potentially beneficial approach to the man-
agement of this clinical problem. Recently, there has 
been a revived interest in the effect of liver cell fractions 
as a means of stimulating liver regeneration. LaBrecque 
and Pesch (14) described a regenerative stimulatory sub-
stance present in the cytosol of regenerating or weanling 
rat livers which had the ability to stimulate DNA syn-
thesis in 40% PH rats. Subsequently Starzl et al. (28), 
using a canine model, identified the presence of hepatic 
growth stimulatory substance in an organelle-free, non-
insulin or glucagon-containing, cytosolic fraction derived 
from livers after 70% PH. Recently, a fraction in rats 
with similar activity has been identified by Francavilla 
et al. (Hepatology 1982; 2:701, Abstract) and termed HSA 
(hepatic stimulatory activity). This substance is able to 
stimulate DNA synthesis and cellular proliferation both 
in vivo and in vitro as further reported in Tables 2 and 
3. Moreover, the present experiments demonstrate that 
the same activities (i.e., enhanced DNA synthesis and 
cell proliferation) are exhibited by partially purified ex-
tracts of crude HSS having molecular weights of 300,000 
and 50,000 daltons. 
A recent extension of the research into these liver-
derived growth factors has been the use of these fractions 
as experimental therapies for acute liver failure in ani-
mals and in humans. Makowka et al. (6) have demon-
strated improved survival and restitution of hepatic his-
tologic deterioration, following acute hepatic necrosis in 
rats induced either by D-GAL or anoxia, using the intra-
peritoneal administration of syngeneic, allogenic and 
xenogenic dispersed liver cells. The same authors re-
ported the efficacy of regenerating liver cytosol in im-
proving the survival of rats with acute D-GAL intoxica-
tion and in reversing the inhibitory effects of ethanol on 
hepatic regeneration following 70% PH (9). More re-
cently, they have also reported the ability of hepatic 
cytosol to reduce the lethal effect of chemotherapeuti-
cally induced acute hepatic necrosis (10). Using cytosol 
preparations derived from 70% hepatectomized dogs, 
Starzl et a1. (28) also have successfully reversed the liver 
atrophy and ultrastructural deterioration seen in dogs 
after portacaval shunting. All of these reports suggest 
that the beneficial effect achieved with the various prep-
arations was due to their ability to promote hepatic DNA 
synthesis and hepatic cellular proliferation. 
The data reported here clearly demonstrate that each 
of the fractions tested was able to stimulate DNA syn-
thesis and hepatocyte proliferation both in vivo and in 
vitro in 60% hepatectomized rats and in D-GAL-intoxi-
cated rats (Tables 2 to 4). 
Although these fractions were able to stimulate hepa-
tocyte proliferation as measured by autoradiography, it 
was only the 300,000 subfraction that resulted in a sig-
nificant improvement in survival in intoxicated rats. 
Double the total protein concentration of the 300,000 
subfraction (i.e., 4 mg) resulted in a further enhancement 
of survival. The apparent discrepancy that all the frac-
tions were active in vivo and in vitro in their ability to 
significantly stimulate DNA synthesis but only the 
300,000 subfraction significantly improved survival is 
open to speculation. One consideration is that as the 
purity of these substances increases, so does the potency 
and ability to influence the kinetics of regeneration. 
Further purification and characterization of these factors 
should resolve this issue. 
These studies do not include serial histology after D-
GAL poisoning. This has already been well characterized 
by various authors for rats receiving various doses of D-
GAL (5-9). Furthermore, recent studies using liver cy-
tosol in a comparable model have demonstrated serial 
improvement in liver morphology in rats that were 
treated with such fractions, at 48 hr after D-GAL poi-
TABLE 4. Effect of HSS and 300,000 subfraction on hepatocyte proliferative activity in rats intoxicated with D-GAL 
Fraction Protein DNA synthesis % labeled nuclei (mg) (cpmjmg of DNA) p< p< 
Saline 3,650 ± 685 0.8 ± 0.25 
HSS 20 18,380 ± 1,958 0.01 8.0 ± 3 0.005 
300,000 subfraction 2 13,520 ± 1,150 0.01 7.5 ± 2.8 0.005 
Three groups of rats, treated similarly to Groups 1, 3 and 5 listed in Table 1, were used for DNA synthesis determination and nuclear labeling 
index. Forty-eight hours following administration of saline and extracts (96 hr after galactosamine administration), all rats received 50 !lCi of 
['Hjthymidine intraperitoneally. Animals were sacrificed 2 hr later and the determinations were performed as reported in "Materials and 
Methods." The values are expressed as mean ± S.E. 
--_ ... _-_ .. _------------
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soning (7, 9).We, as well as others (5, 7-9), have evalu-
ated liver functions biochemically and have demon-
strated that the degree of liver injury was equivalent in 
all groups receiving D-GAL at 48 hr regardless of addi-
tional treatment (unpublished data). Therefore, the dif-
ferences in survival observed in these studies are related 
to the differences in treatment at 48 hr. 
The timing of administration in the in vivo model of 
the various fractions tested in these studies is critical. It 
has already been demonstrated using a similar model 
and liver cytosol that 48 hr after D-GAL treatment was 
the optimal time and specifically that earlier administra-
tion of the fractions did not result in enhancement of 
survivorship. It is also known that the lesion is well 
established by 48 hr and that the mortality rate is con-
sistent (2, 3). Furthermore, the possibility that the var-
ious fractions administered in these studies contained 
uridine (2, 3, 9), and that this was responsible for the 
reversal of the hepatic failure no longer exists. This 
repo'rt does, however, provide direct histopathological 
data, demonstrating that rats poisoned with D-GAL and 
then treated at 48 hr with HSS and 300,000 subfraction 
resulted in a significant increase in the DNA synthetic 
activity and in the percentage of labeled nuclei when 
compared to rats receiving saline alone (Table 4, auto-
radiographic data). The evidence reported here, com-
bined with that of other authors (5-9), therefore, strongly 
suggest that increased survivorship in this model 
is related to an effect of these fractions on hepatic 
regeneration. 
Each of the preparations studied in the present exper-
iments was completely free of recognizable hormones 
such as insulin, glucagon and EGF. In fact, none of these 
hormones was detectable by radioimmunoassay, and the 
fractions have physiochemical characteristics which dif-
fer from each of these hormones. Specifically, insulin 
and glucagon are soluble in alcohol, while HSS is precip-
itated in alcohol. EGF is soluble in acid solution while 
HSS is precipitated. 
This report presents further evidence to support the 
hypothesis that the liver is the source of a growth fac-
tor(s) able to artificially promote hepatic DNA synthesis, 
hepatocyte proliferation and the restitution of a histo-
logically injured liver. Furthermore, the identification of 
such a growth factor for the liver may represent a sig-
nificant advance for the management of clinical fulmi-
nant hepatic failure. 
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